These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 11557491

  • 1. In vitro activity of the ketolide ABT-773.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2922-4. PubMed ID: 11557491
    [Abstract] [Full Text] [Related]

  • 2. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.
    Credito KL, Lin G, Pankuch GA, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2001 Jan; 45(1):67-72. PubMed ID: 11120946
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Brueggemann AB, Doern GV, Huynh HK, Wingert EM, Rhomberg PR.
    Antimicrob Agents Chemother; 2000 Feb; 44(2):447-9. PubMed ID: 10639382
    [Abstract] [Full Text] [Related]

  • 4. Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.
    Rospide MF, Biedenbach DJ, Jones RN.
    Int J Antimicrob Agents; 2001 Jun; 17(6):451-5. PubMed ID: 11397614
    [Abstract] [Full Text] [Related]

  • 5. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM, Prause JL, Danziger LH, Pendland SL.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of the new ketolide ABT-773 against community acquired respiratory tract isolates and Viridans Streptococci.
    Casellas JM, Tomé G, Visser M, Gliosca L.
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):107-12. PubMed ID: 11858905
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
    Barry AL, Fuchs PC, Brown SD.
    Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD, Rybak MJ.
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
    Citron DM, Appleman MD.
    Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
    [Abstract] [Full Text] [Related]

  • 10. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci.
    Singh KV, Malathum K, Murray BE.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3640-3. PubMed ID: 11709359
    [Abstract] [Full Text] [Related]

  • 11. Antipneumococcal activity of ABT-773 compared to those of 10 other agents.
    Davies TA, Ednie LM, Hoellman DM, Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1894-9. PubMed ID: 10858350
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children.
    Johnson CN, Benjamin WH, Gray BM, Crain MC, Edwards KM, Waites KB.
    Int J Antimicrob Agents; 2001 Dec; 18(6):531-5. PubMed ID: 11738340
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.
    Dubois J, St -Pierre C.
    Diagn Microbiol Infect Dis; 2001 Dec; 40(1-2):35-40. PubMed ID: 11448561
    [Abstract] [Full Text] [Related]

  • 14. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.
    Abbanat D, Webb G, Foleno B, Li Y, Macielag M, Montenegro D, Wira E, Bush K.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):309-15. PubMed ID: 15616310
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.
    Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N.
    J Med Chem; 1998 Oct 08; 41(21):4080-100. PubMed ID: 9767644
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: synthesis and structure-activity relationships.
    Nomura T, Iwaki T, Narukawa Y, Uotani K, Hori T, Miwa H.
    Bioorg Med Chem; 2006 Jun 01; 14(11):3697-711. PubMed ID: 16460944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.